Patents by Inventor Robert Pejchal

Robert Pejchal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230312712
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: February 24, 2023
    Publication date: October 5, 2023
    Applicant: Alectro LLC
    Inventors: Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
  • ANTI-CD3-BINDING DOMAINS AND ANTIBODIES COMPRISING THEM, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20230151097
    Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
    Type: Application
    Filed: November 11, 2022
    Publication date: May 18, 2023
    Inventors: Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
  • Anti-TREM2 antibodies and methods of use thereof
    Patent number: 11634489
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: April 25, 2023
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230047941
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 9, 2022
    Publication date: February 16, 2023
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
  • HIGH AFFINITY ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20230002487
    Abstract: Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.
    Type: Application
    Filed: June 8, 2020
    Publication date: January 5, 2023
    Inventors: Robert PEJCHAL, Caitlin STEIN, Julia McCREARY
  • Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
    Patent number: 11542330
    Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: January 3, 2023
    Assignee: Adimab, LLC
    Inventors: Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
  • FC VARIANTS WITH REDUCED EFFECTOR FUNCTION
    Publication number: 20220396622
    Abstract: The present invention provides Fc variants and polypeptides, e.g., antibodies and Fc fusion proteins, comprising such Fc variants. In particular, Fc variants with diminished effector function as a consequence of hinge region and CH2 domain mutations, e.g., LALE-PG, are provided. Such variants maintain antigen-binding and favorable developability profiles and may display improved expressability.
    Type: Application
    Filed: June 24, 2022
    Publication date: December 15, 2022
    Inventors: Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Michael Brown, Anthony Cooper
  • ENGINEERED PH-DEPENDENT ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20220380463
    Abstract: Engineered pH-dependent anti-CD3 binding domains and antibodies and/or antigen-binding domains comprising same, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 1, 2022
    Inventors: James GEOGHEGAN, Bianka PRINZ, Robert PEJCHAL
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220348656
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 9, 2022
    Publication date: November 3, 2022
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
    Publication number: 20220251219
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: April 14, 2022
    Publication date: August 11, 2022
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
  • Anti-Sortilin antibodies and methods of use thereof
    Patent number: 11396546
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: July 26, 2022
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper
  • METHODS OF INCREASING PROGRANULIN LEVELS USING ANTI-SORTILIN ANTIBODIES
    Publication number: 20220185899
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY
    Publication number: 20220185898
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
  • ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220162309
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 26, 2022
    Applicant: ALECTOR LLC
    Inventors: Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
  • Methods of use of anti-Sortilin antibodies for treating a disease, disorder, or injury
    Patent number: 11339223
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: May 24, 2022
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
  • Anti-CD33 antibodies and methods of use thereof
    Patent number: 11254743
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: February 22, 2022
    Assignee: ALECTOR LLC
    Inventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
  • Methods of increasing progranulin levels using anti-Sortilin antibodies
    Patent number: 11208488
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 28, 2021
    Assignee: Alector LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
  • Isolated nucleic acids encoding anti-sortilin antibodies
    Patent number: 11186645
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: November 30, 2021
    Assignee: Alector LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
  • ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210139581
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: May 7, 2020
    Publication date: May 13, 2021
    Applicant: ALECTOR LLC
    Inventors: Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
  • FC VARIANTS WITH REDUCED EFFECTOR FUNCTION
    Publication number: 20210087271
    Abstract: The present invention provides Fc variants and polypeptides, e.g., antibodies and Fc fusion proteins, comprising such Fc variants. In particular, Fc variants with diminished effector function as a consequence of hinge region and CH2 domain mutations, e.g., LALE-PG, are provided. Such variants maintain antigen-binding and favorable developability profiles and may display improved expressability.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 25, 2021
    Inventors: Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Michael Brown, Anthony Cooper